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Aims Pulmonary vein isolation (PVI) with cryoenergy delivered through a balloon is a new approach in
the treatment of atrial ﬁbrillation (AF), but long-term follow-up is lacking. The aim of this study was
to provide insight in the success rate and the incidence of recurrences.
Methods and results Patients with symptomatic AF despite anti-arrhythmic drugs (AADs) were treated
with cryoballoon PVI. Daily transtelephonic ECG monitoring, 24 h Holter-ECG, and an arrhythmia-
focused questionnaire were used to document AF. One hundred and forty-one patients completed a
follow-up of 457+252 days. Before ablation, Holter-ECG showed AF in 45%, including 16% continuous
AF throughout the recording. Event recording revealed a median AF burden of 26%. The questionnaire
showed a median of weekly AF complaints lasting for hours. All but one patient had successful PVI with a
single procedure. After ablation, AF (deﬁned as lasting for more than 30 s) was seen in 11% of Holter-
ECGs, with 1% continuous AF. The event recording showed an AF burden of 9%. The median patient
reported no more AF-related symptoms. Recurrence during the ﬁrst 3 months was predictive for later
recurrence. A second procedure was performed in 24 patients. The freedom of AF was 59% without
AADs after 1,2 procedures. Four right phrenic nerve paralyses occurred, all resolving within 6
months. No PV stenoses were observed.
Conclusion Pulmonary vein isolation with a cryothermal balloon is an effective treatment for paroxys-
mal AF, resulting in a clinical success rate comparable to studies involving radiofrequency ablation.
Temporary right phrenic nerve paralysis is the most important complication.
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Introduction
Pulmonary vein isolation (PVI) has become an important
treatment for patients with atrial ﬁbrillation (AF). Reports
that show more than 80% freedom of paroxysmal AF during
long-term follow-up have been published.
1 A large number
of different approaches and techniques are currently
routinely employed to achieve that goal, but the procedure
remains technically challenging. The development of
balloon cryoablation has recently proven to be safe and
effective for PVI in animals
2–5 and humans.
6 While greatly
simplifying the technical ablation aspects and showing 60%
freedom of AF after a 3-month follow-up period, long-term
results remained to be studied. The scope of our study is
to report recurrences of AF during the ﬁrst year and com-
plications after a cryoballoon PVI, using a wide array of
follow-up modalities.
Methods
Inclusion
Between August 2005 and August 2007, a cryothermal balloon
approach was used for all consecutive patients who were selected
for circumferential PVI because of paroxysmal AF. All patients
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symptomatic paroxysmal AF without major structural heart
disease (normal left ventricular ejection fraction, no or only
minor mitral insufﬁciency, normal to slightly enlarged left atrial
diameter, assessed in the long parasternal axis). None of the
patients had previously been ablated in the left atrium, and all of
them had episodes of AF despite concomitant anti-arrhythmic
drug (AAD) treatment.
Screening before and assessment after ablation
Event recording
During 1 month before ablation, patients were instructed to use an
event recorder for transmitting a daily transtelephonic 30 s ECG
strip at a ﬁxed hour. When symptoms were experienced, additional
strips could be sent. This was continued until 3 months after abla-
tion. The obtained ECG strips were coded as sinus rhythm, atrial
ﬂutter, atrial tachycardia, or AF. The AF burden was deﬁned as
the percentage of days on which an AF episode was transmitted.
The compliance of patients with this follow-up method was moni-
tored, and when no data were sent in, they were reminded to do so.
24 h Holter
All patients were scheduled for 24 h Holter recording at baseline
and at 3 months follow-up. Thereafter, additional recordings were
made at the physician’s discretion as guided by patient complaints.
Each Holter was analysed for the presence of AF, runs of atrial
tachycardia, and atrial premature beats. Sustained AF was deﬁned
as lasting for more than 30 s. If AF was present during the
entire recording, it was coded as continuous. The time in AF was
measured.
Quality of life questionnaire
All patients were asked to ﬁll out a questionnaire pertaining to their
complaints before ablation and at 3 months after PVI. Both the
frequency and the duration of AF-related complaints were graded
according to a previously described and validated protocol.
6,7
After ablation, they were asked to grade their overall improvement
at 3 months.
Outpatient screening and follow-up
All patients were evaluated by one of two qualiﬁed physicians (L.J.
and Y.V.B.) before ablation and at 3-month intervals after ablation.
At these times, an extensive history, physical examination, and
12-lead ECG recordings were made. Transthoracic echocardiography
and multislice CT were performed at baseline and at 3 months.
Echocardiography was used to measure the left atrial dimensions
and calculate the left atrial volume. Multislice CT was used to
create a 3D anatomical reconstruction of the left atrium and to
measure the ostial dimensions of the pulmonary veins. During
these scheduled outpatient visits, additional rhythm registrations
and cardiac imaging were performed at the physician’s discretion
to investigate complaints or register recurrence of AF. The same
was done at unscheduled visits at the outpatient clinic and at the
emergency department.
Procedure
A detailed description of the cryoballoon ablation procedure has
been given in a previous report.
6 A cavo-tricuspid isthmus ablation
was performed in seven patients because of documented isthmus-
dependent ﬂutter. The cryoballoon size was selected upon
availability until February 2007 and had to be larger than the PV
diameter on the CT scan. From February 2007 on, the 28 mm size
was preferred. Redo procedures were performed with the same
protocol as the primary procedure.
Anti-arrhythmic drugs
Anti-arrhythmic drugs were stopped 1 week before ablation. After
the PVI, patients were given their habitual drug regime until 3
months after ablation. If no recurrence during the ﬁrst 3 months
was observed, the AADs were stopped. If recurrences were limited
to the ﬁrst month or if a reduction of AF burden was obtained of
more than 90%, AADs were stopped at 3 months. If not, either the
drug regime was altered or a redo procedure was advised. If recur-
rence occurred after AAD cessation, they were restarted and
altered if necessary.
Endpoints
Recurrence of AF was deﬁned as the presence of at least one record-
ing of AF after ablation, regardless of its origin (12-lead ECG, trans-
telephonic rhythm strip, 24 h Holter recording, unsolicited tracing).
Additional endpoints were improvement of quality of life as per-
ceived by the patient, reduction of AF burden with  90%, and dis-
appearance of AF on the 24 h Holter recording. The advice for a
second procedure was based on the presence of early and late symp-
tomatic recurrence under AAD. Finally, the results were reported
according to the HRS/EHRA/ECAS recommendations.
1
Follow-up after the second procedure
The follow-up after a second PVI was performed in the same way
as the ﬁrst procedure, omitting the baseline Holter and event
recording.
Statistical analysis
Continuous variables were expressed as mean+SD if normally
distributed, or otherwise by median. Continuous variables were
evaluated using Student’s t-test or one-way analysis of variance.
Categorical variables were expressed as percentages. The x
2 test
was used for the analysis of categorical variables. A paired non-
parametric test was used when appropriate. The Wilcoxon rank
test was used to compare the change in symptom frequency and
duration scores over time for each patient. Actuarial event-free
rates from atrial ﬁbrillation were calculated according to the
Kaplan–Meier method and were compared by use of the log-rank
test. The level of statistical signiﬁcance was set at 0.05.
Results
Patient description
The ﬁrst 141 consecutive patients treated with this tech-
nique at our institution were included in this study. Two
patients were excluded from the follow-up analysis: one
was excluded due to equipment failure at the time of
ablation, and one developed acute pulmonary oedema for
which the procedure was aborted before ablation. The
demographic data are presented in Table 1.
Table 1 Patient demographics
Patient number (n) 141
Male/female 100/41
Age (years) 56+9
Follow-up duration (days) 457+242
Left atrial diameter (mm) 42+7
Valvular heart disease (n)5
Arterial hypertension (n)1 9
Thyroid disease (n)7
Amiodarone treatment (n)3 5
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Pulmonary vein isolation was achieved in 139 patients within
one procedure. This was done with a 23 mm balloon in 33
patients, a 28 mm balloon in 99 cases, and both sizes were
used in seven cases. A Freezor Max (Cryocath) was used to
complete PVI in 56 patients (a total of 86 veins), on
average 4+2 applications were needed to complete the
isolation. The mean procedure time was 207+79 min and
the mean ﬂuoroscopy time 50+28 min. A total number of
1243 applications was given with the balloon with a mean
of 9+3 per patient. With the Freezor Max, 242 applications
were given. Eight patients experienced pericardial effusion,
including one due to rupture of the left superior pulmonary
vein caused by distal cryoballoon inﬂation and one had a
haematopneumothorax. Right phrenic nerve paralysis was
observed in spite of precautions in four patients.
Follow-up duration
The mean follow-up in this prospective study was 457+252
days, until 31st March 2008.
Event recording
A total number of 2019 rhythm strips before and 7986 after
ablation were available, of which 534 of 2019 (26%) before
and 686 of 7986 (9%) after ablation showed AF. Of the
entire group, 119 patients had reliably transmitted trans-
telephonic rhythm strips before and after ablation. On
average, they transmitted 17+7 strips/month before abla-
tion and 20+9 strips/month after ablation. Of this group,
42 (35%) patients showed no AF episodes on the baseline
event recording. Their AF burden before and after ablation
is represented in Figure 1. The reduction in AF burden was
highly signiﬁcant (P , 0.0001) (Table 2). In total, 66 patients
(55%) did not have any recurrence of AF after ablation on
this event recording (P , 0.005). When looking at patients
with recurrence, the AF burden still showed a signiﬁcant
reduction after ablation (P , 0.0001). The baseline burden
between those with and without recurrence did not differ
signiﬁcantly.
24 h Holter recording
In total, 128 patients had performed a 24 h Holter recording
before and 129 patients 3 months after ablation. Before
ablation, 58 (45%) patients had AF documented on their
Holter recording, of whom 21 (16%) patients had continuous
AF during the entire 24 h. After ablation, this decreased to
14 (11%) patients with AF on the Holter, of whom 1 (1%)
patient had continuous AF during the entire 24 h. The
median time in AF for those with paroxysmal AF decreased
from 19 to 8%. Heart rate during sinus rhythm did not
change signiﬁcantly before and after ablation (67+11 vs.
68+10 b.p.m.).
Quality of life
Patients assessed the frequency, duration, and improvement
of their complaints. The median scores (as explained in
Table 3) for frequency and duration before were, respect-
ively, 3 (range 1–5) and 3 (range 1–5), being weekly episodes
lasting for one or more hours. After ablation this was signiﬁ-
cantly reduced to median values of 1 and 1 (ranges for both
1–5), being no more complaints (P , 0.01). Paired data were
available in 125 patients. After a 3-month follow-up period,
90 (72%) of the patients considered themselves improved, 22
(18%) considered their symptoms as equal, and 13 (10%) con-
sidered their symptoms as worse.
Clinical long-term follow-up results
From the initial procedure, until redo or 31st March 2008,
an additional 597 rhythm strips and 191 Holter recordings
were obtained from the entire group either at the routine
follow-up visits or when presenting with complaints. On
average, a patient had 10+9 rhythm strips taken during
the rest of his follow-up and had 1.3+0.7 Holters per-
formed after the initial 3 months.
Freedom from recurrent atrial ﬁbrillation
Combining all these resources, actuarial event-free rates
from any AF were calculated (Figure 2). The event-free
Figure 1 Atrial ﬁbrillation (AF) burden as calculated from transte-
lephonic ECG recordings sorted ascendingly by the burden before
pulmonary vein isolation (before) and burden sorted ascendingly
after isolation (after). The area between both curves represents
the reduction in AF burden for the entire group.
Table 2 Results of event recording 1 month before and 3 months after ablation
Total group Recurrence No recurrence
Before After P Before After P Before After P
Proportion with AF n 77/119 53/119 ,0.005 41/53 53/53 NA 36/66 0/66 NA
AF burden (%) Mean+SD 27+32 9+17 ,0.0001 33+34 19+21 ,0.0005 21+33 0 NA
Median (range) 14 (0–100) 0 (0–92) 20 (0–100) 10 (1–92) 5 (0–100) 0 (0–0)
Data from daily transtelephonic event recording for the patients with recordings before and after the intervention. Burden means the percentage of days
with AF present in a recording. AF, atrial ﬁbrillation; NA, not applicable; n, number; SD, standard deviation.
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3 months were blanked, and the curve was constructed from
90 days on, the event-free survival rate at 365 days was 73%
(P , 0.0001). When patients with and without a recurrence
in the ﬁrst 3 months were compared (Figure 3), it became
clear that a recurrence in the ﬁrst 3 months was highly pre-
dictive for recurrence after 3 months, whereas the absence
of events in the ﬁrst 3 months was highly predictive for a low
recurrence rate (log-rank 23, P , 0.0001).
Recurrence of atrial ﬁbrillation and anti-arrhythmic
drug treatment
After one procedure, 49% (68/139) were free from AF without
AADs. Of the remaining 51% (71/139) with AF recurrence, 27%
(37/139) were advised to undergo a second procedure and
24% (34/139) continued on medical treatment due to a
decrease in AF burden. In total, 34% (47/139) continued on
medical treatment and 17% (24/139) agreed to undergo a
second procedure. These data are represented in Figure 4.
Recurrence of atrial ﬁbrillation after a second
procedure
Of the 37 patients to whom a redo procedure was
advised (always after 3 months), 24 underwent a second pro-
cedure. On average, there was reconduction to 3+1P V .
Reconduction was found in 20/24 (83%) left superior PVs,
in 22/24 (92%) left inferior PVs, in 17/24 (71%) right superior
PVs, and in 14/24 (58%) right inferior PVs. During this second
procedure, all reconducting veins were successfully isolated
with the same technique. The average follow-up after the
second procedure was 225+137 days. During this follow-up,
eight patients had an early recurrence after a mean interval
of 15 days; three had a late recurrence after 3 months,
making the total number of patients with recurrence after
a redo procedure 46% (11/24).
Overall recurrence of atrial ﬁbrillation
After a mean of 1,2 procedures, 82/139 (59%) of the patients
were free from AF without AADs and 57/139 (41%) of the
patients were under medical treatment, with a reduced AF
burden.
Long-term complications
Multislice CT scan showed that there was no signiﬁcant
difference in PV diameter before and after the procedure.
The mean PV diameter was 18.0+3.8 mm before the pro-
cedure vs. 18.1+3.7 mm after. Two patients complained
of haemoptysis during the ﬁrst month after PVI, but
without PV stenosis on the multislice CT scan. In both of
these patients, the problem did not recur after temporary
cessation of the anticoagulation therapy. The haemato-
pneumothorax resolved completely. Two patients needed
transfusion, because of a haematoma in the groin and a
retroperitoneal bleeding, respectively. Two arteriovenous
ﬁstula were reported. Four asymptomatic right phrenic
nerve paralyses were observed, persisting at discharge.
Three patients had recovery of their diaphragm movement
at 3 months; all four had recovered at 6 months. One peri-
mitral ﬂutter was documented and successfully ablated.
Discussion
We describe in this paper the clinical 1-year follow-up of
a large consecutive group of patients treated with a
Figure 2 Event-free survival curve for atrial ﬁbrillation (AF) after a
single ablation procedure. The two curves represent the same
patient population. The upper curve (AF only after 3 months) rep-
resents the event-free survival after a 3-month blanking period;
the second curve (All AF) represents the event-free survival
without the 3-month blanking period. The patient numbers of
both groups are represented at the bottom.
Figure 3 Event-free survival curve for atrial ﬁbrillation (AF) after a
single ablation procedure, employing 3-month blanking period. The
upper curve (no early recurrence) is the patient population that did
not have recurrence of AF during the blanking period. The lower
curve (with early recurrence) represents the group that experienced
recurrence of AF during the 3-month blanking period. Patient
numbers of both groups are represented at the bottom.
Table 3 Score for AF episode frequency and duration
Score Frequency of AF episodes Duration of AF episodes
1 None None
2 Monthly Minutes/seconds
3 Weekly Hours
4 Daily Days
5 Incessant Incessant
AF, atrial ﬁbrillation.
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had a clinical freedom from AF comparable to studies using
radiofrequency (RF) ablation. Further, early recurrence was
indicative for later clinical failure and associated with
reconduction to the veins.
Complications
The potential advantages of cryoenergy were already
described in animals and have been suggested for humans
as well.
3,8 No thromboembolism was seen in our group,
which seems equivalent to similar RF populations. In con-
trast to ostial RF ablation,
1 comparison of ostial PV dia-
meters obtained from serial CT shows again that
cryothermal energy, although being delivered at the antral
and ostial regions, causes no PV stenosis.
8 Although a rare
complication in RF ablation, we found a 4% incidence of
right phrenic nerve paresis, with complete recovery in all
of them at the end of follow-up. A large multicentre study
found this in around 8% of the cases, also reporting complete
recovery in all. This complication was also reported in
different balloon delivery systems, independent of the
energy used (ultrasound, high intensity ultrasound).
9,10 In
RF ablation, the complete recovery of this nerve can only
be expected in 66% and partial recovery in 17%.
11
Freedom of atrial ﬁbrillation
The event-free survival in our analysis is comparable with
data in the worldwide survey on RF ablation of paroxysmal
and persistent AF.
12 After a single procedure, 73% reported
symptom improvement, coinciding roughly with the advice
for a second procedure in 23%, which was given after objec-
tive recurrences in spite of AAD therapy after 3 months.
Previously published cryoablation studies in the literature
show success rates varying between 56% freedom of AF
after 1 year (including 21% on AAD)
8 and 71% freedom of
AF after 4 years (including 22% on AAD) with a segmental
isolation.
13 A cryoballoon study with a very limited number
of patients shows freedom of AF in 90% of the cases after
6 months,
14 whereas a multicentre study reveals sinus
rhythm in 74% of the patients after 1 year without AAD, in
paroxysmal AF, and 42% without AAD in persistent AF.
15 Our
study yields a lower success rate, with 59% being free from
AF at 1 year without the use of AAD. This is probably due
to a difference in follow-up method, since no large differ-
ence in patient characteristics is obvious.
Reconduction
Previous studies have shown AF recurrence to be associated
with reconduction in the PVs.
16–18 This was also true for our
study. In the patients considered for a repeat procedure,
we found high rates of reconduction from the left atrium
to the PVs.
Limitations
The major limitation of this prospective study is that it
is observational, and therefore, substantive conclusions
cannot be drawn regarding its relative advantages or disad-
vantages compared with RF ablation. For this a randomized
head-to-head comparison would be required.
A second limitation is the less intense follow-up after the
initial 3-month period. Although a large effort was made to
document long-term clinical efﬁcacy, daily transtelephonic
event recording over a very long period proved to decrease
patient compliance dramatically, so that this was not a
feasible method.
Conclusions
The data we present indicate that cryoablation with a
balloon delivery system yields similar results to those
reported on RF ablation, and comparable to other cryobal-
loon trials. An acceptable complication rate was observed.
Figure 4 Graphical representation of the overall 1-year clinical outcome after a mean of 1,2 procedures, presented as patient numbers. AF,
recurrence of atrial ﬁbrillation; AAD, anti-arrhythmic drugs.
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